Advances in Immunotherapy and Targeted Therapy for Gastric Cancer: A Comprehensive Review
British Journal of Hospital Medicine,
Год журнала:
2025,
Номер
86(3), С. 1 - 24
Опубликована: Март 26, 2025
Gastric
cancer
remains
one
of
the
most
prevalent
and
lethal
malignancies
worldwide,
characterized
by
poor
survival
rates,
particularly
in
advanced
stages.
In
recent
years,
a
paradigm
shift
gastric
treatment
has
been
witnessed
with
introduction
immunotherapy
targeted
therapies.
This
review
provides
detailed
examination
current
immunotherapeutic
strategies,
including
adoptive
cell
therapy
(ACT),
immune
checkpoint
inhibitors
(ICIs),
vaccines.
Additionally,
it
explores
advancements
therapies,
focusing
on
human
epidermal
growth
factor
receptor
2
(HER2)
vascular
endothelial
(VEGFR)
signaling
pathways,
as
well
emerging
targets
such
claudin
18.2.
Clinical
trials
investigating
chimeric
antigen
T-cell
(CAR-T)
therapy,
receptor-engineered
(TCR-T)
natural
killer
(NK)
cell-based
treatments
have
shown
promise,
when
combined
conventional
chemotherapeutic
regimens.
However,
challenges
cytokine
release
syndrome,
immune-related
toxicities,
scalability
issues
remain
significant.
The
combination
therapies
represents
promising
approach
to
enhance
outcomes.
Future
directions
emphasize
need
overcome
resistance
mechanisms
refine
strategies
improve
efficacy
while
reducing
adverse
effects.
aims
elucidate
landscape
explore
their
potential
shaping
future
clinical
management
for
this
devastating
disease.
Язык: Английский
Machine learning-based prognostic modelling of NK cells in PAAD for immunotherapy guidance
Li Li,
Wu Zz,
Wanxing Duan
и другие.
Discover Oncology,
Год журнала:
2025,
Номер
16(1)
Опубликована: Апрель 20, 2025
Язык: Английский
Staying on target in gene and cell therapy
Molecular Therapy,
Год журнала:
2024,
Номер
32(9), С. 2801 - 2802
Опубликована: Авг. 23, 2024
Язык: Английский
Advancing the next generation of cancer treatment with circular RNAs in CAR-T cell therapy
Sanxiong Huang,
Juling Xu,
Natalia Baran
и другие.
Biomedicine & Pharmacotherapy,
Год журнала:
2024,
Номер
181, С. 117753 - 117753
Опубликована: Дек. 1, 2024
Chimeric
Antigen
Receptor
T-cell
(CAR-T)
therapy
has
revolutionized
the
treatment
of
hematological
malignancies.
However,
its
effectiveness
against
solid
tumors
remains
constrained
by
challenges
such
as
exhaustion,
limited
persistence,
and
off-target
effects.
These
highlight
critical
gaps
in
current
CAR-T
cell
therapeutic
strategies,
particularly
for
tumor
applications.
Circular
RNAs
(circRNAs)
represent
a
transformative
class
non-coding
RNAs,
known
their
exceptional
stability
precise
regulatory
functions,
positioning
them
promising
candidates
enhancing
next-generation
therapies.
Notably,
circRNAs
can
bridge
gap
between
preclinical
research
clinical
application
offering
innovative
solutions
to
overcome
technical
hurdles
improve
outcomes.
Despite
potential,
remain
underexplored
therapies
tumors,
presenting
significant
opportunity
innovation.
The
mechanisms
through
which
modulate
specificity
are
not
yet
fully
understood,
challenges,
achieving
efficient
targeted
circRNA
delivery,
still
need
be
addressed.
This
review
highlights
importance
integrating
into
enhance
specificity,
minimize
effects,
durability.
By
emphasizing
potential
identifying
key
gaps,
this
provides
roadmap
advancing
setting
stage
next
generation
personalized
cancer
treatments.
Язык: Английский